Sodium benzoate for the treatment of behavioral and psychological symptoms of dementia (BPSD): A randomized, double-blind, placebo-controlled, 6-week trial.

Chia-Hung Lin, PK Chen, SH Wang, HY Lane

Research output: Contribution to journalJournal Article peer-review

19 Scopus citations

Abstract

Sodium benzoate, a D-amino acid oxidase (DAAO) inhibitor, improved cognitive function of early-phase Alzheimer's disease (AD) after 24-week treatment. This study examined benzoate treatment for behavioral and psychological symptoms of dementia (BPSD). In a double-blind, 6-week trial, 97 patients with BPSD were randomized to receive placebo or benzoate (mean dose: 622.0 mg/day). The primary outcomes were ADAS-cog and BEHAVE-AD. Two treatments showed similar safety and primary and secondary outcomes. Compared to antecedent 24-week, higher-dose treatment for early-phase AD, benzoate appeared ineffective in this 6-week trial. Longer-duration, higher-dose trials are warranted to clarify its efficacy for BPSD.
Original languageAmerican English
Pages (from-to)269881119849815
JournalJournal of psychopharmacology (Oxford, England)
Volume33
Issue number8
DOIs
StatePublished - 2019

Fingerprint

Dive into the research topics of 'Sodium benzoate for the treatment of behavioral and psychological symptoms of dementia (BPSD): A randomized, double-blind, placebo-controlled, 6-week trial.'. Together they form a unique fingerprint.

Cite this